Phenotypic detection of some drug resistance and virulence factors among Helicobacter pylori isolated from clinical sources in Iraq

M. J. A. Hussein; H. R. A. Al-Fahham; A. S. Abed

doi:10.15421/0225007

M. J. A. Hussein Al-Bayan University
H. R. A. Al-Fahham University of Jabir Ibn Hayyan for Medical and Pharmaceutical Science
A. S. Abed Jabir Ibn Hayyan University of Medical and Pharmaceutical Sciences

Keywords: Helicobacter pylori, gastritis, metronidazole, clarithromycin, amoxicillin, tetracycline.

Abstract

Helicobacter pylori colonizes the gastrointestinal tract and can produce diseases leading to gastric problems ranging from gastritis to peptic ulcers or macroadenomas. In these cases, t reatment is critical . H owever, antibiotic resistance could potentially reduce the antibiotic efficacy leading to disease progression . The present study aimed to characterize the resistance profile of commonly used antibiotics in our community, including metronidazole, clarit h romycin, amoxicillin, and tetracycline. Helicobacter pylori were cultured and characterised for identification and virulence factor production. For H. pylori isolates from individuals with gastrointestinal illnesses, a set of drugs, including clarithromycin, tetracycline, amoxicillin and metronidazole, w as used in the disk diffusion and agar dil u tion procedures. 25 individuals with gastrointestinal illnesses out of 100 patients tested positive for H. pylori is o lates. After that, an antibiotic sensitivity test was performed, and the results showed that 9/25 (36%) of the isolates were resistant to metronidazole (MICs ≥ 6 μg/L), while 7/25 (28%) were resistant to amoxicillin (MICs ≤ 1 μg/mL), while resistance rates were 6/25 (24%) to tetracycline and 3/25 (12%) to clarithromycin (MICs ≤ 4 μg/mL). The present study confirmed that resistance exists with metronidazole being the highest while clarithr o mycin, amoxicillin, and tetracycline have lower resistance than metronidazole.

References

Álvarez, A., Moncayo, J. I., Santacruz, J. J., Santacoloma, M., Corredor, L. F., & Reinosa, E. (2009). Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the Western Central Region of Colombia. Antimicrobial Agents and Chemotherapy, 53(9), 4022–4024.

Ang, T. L., Fock, K. M., Ang, D., Kwek, A. B. E., Teo, E. K., & Dhamodaran, S. (2016). The changing profile of Helicobacter pylori antibiotic resistance in Singapore: A 15-year study. Helicobacter, 21(4), 261–265.

Bashir, S. K., & Khan, M. B. (2023). Overview of Helicobacter pylori infection, prevalence, risk factors, and its prevention. Advanced Gut and Microbiome Research, 2023, 9747027.

Bedoya-Gómez, I. J., Alvarez-Aldana, A., Moncayo-Ortiz, J. I., Guaca-González, Y. M., Santacruz-Ibarra, J. J., Arturo-Arias, B. L., Castañeda-Chávez, L. J., Leon Rodriguez, D. A., & Beltrán-Angarita, L. (2020). Surveillance of the antimicrobial resistance rates of Helicobacter pylori ten years later in the Western Central Region, Colombia. Digestive Diseases, 38(3), 196–203.

Botija, G., García Rodríguez, C., Recio Linares, A., Campelo Gutiérrez, C., Pérez-Fernández, E., & Barrio Merino, A. (2021). Resistencias antibióticas y tasas de erradicación en infección por Helicobacter pylori. Anales de Pediatría, 95(6), 431–437.

Bouihat, N., Burucoa, C., Benkirane, A., Seddik, H., Sentissi, S., Al Bouzidi, A., Elouennas, M., & Benouda, A. (2017). Helicobacter pylori primary antibiotic resistance in 2015 in Morocco: A phenotypic and genotypic prospective and multicenter study. Microbial Drug Resistance, 23(6), 727–732.

Boyanova, L., Gergova, G., Evstatiev, I., Spassova, Z., Kandilarov, N., Yaneva, P., Markovska, R., & Mitov, I. (2016). Helicobacter pylori resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. Infectious Diseases, 48(1), 56–62.

Boyanova, L., Kandilarov, N., Hadzhiyski, P., Gergova, R., Gergova, G., & Markovska, R. (2022). Increase in amoxicillin resistance in Helicobacter pylori from Bulgarian patients over 15 years. Diagnostic Microbiology and Infectious Disease, 104(1), 115746.

Chen, D., Cunningham, S. A., Cole, N. C., Kohner, P. C., Mandrekar, J. N., & Patel, R. (2017). Phenotypic and molecular antimicrobial susceptibility of Helicobacter pylori. Antimicrobial Agents and Chemotherapy, 61(4), e02530-16.

Darweesh, O., Abdulrazzaq, G. M., Al-Zidan, R. N., Bebane, P., Merkhan, M., Aldabbagh, R., & AlOmari, N. (2021). Evaluation of the pharmacologic treatment of COVID-19 pandemic in Iraq. Current Pharmacology Reports, 7(4), 171–178.

Dekhnich, N., Ivanchik, N., Kozlov, R., Alimov, A., Steshits, A., Kirsov, P., & Pandav, K. (2018). Dynamics of antimicrobial resistance of Helicobacter pylori isolates in the Smolensk region of Russian Federation. Helicobacter, 23(6), e12545.

Di Giulio, M., Di Campli, E., Di Bartolomeo, S., Cataldi, V., Marzio, L., Grossi, L., Ciccaglione, A. F., Nostro, A., & Cellini, L. (2016). In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy. Scandinavian Journal of Gastroenterology, 51(3), 263–269.

Fabricio Guaman, J., Bayas-Morejon, I. F., Arcos, V., Tigre-Leon, A., Lucio-Quintana, A., Salazar, S., Gaibor-Chavez, J., & Ramon Curay, R. (2018). Detection of Helicobacter pylori from human biological samples (feces) by antigenic screening and culture. Jundishapur Journal of Microbiology, 11(7), e66721.

Goudarzi, M., Heidary, M., Azad, M., Fazeli, M., & Goudarzi, H. (2016). Evaluation of antimicrobial susceptibility and integron carriage in Helicobacter pylori isolates from patients. Gastroenterology and Hepatology from Bed to Bench, 9(Suppl1), S47–S52.

Gunnarsdottir, A. I., Gudjonsson, H., Hardardottir, H., Jonsdottir, K. D., & Bjornsson, E. S. (2017). Antibiotic susceptibility of Helicobacter pylori in Iceland. Infectious Diseases, 49(9), 647–654.

Hanafi, A., Lee, W. C., Loke, M. F., Teh, X., Shaari, A., Dinarvand, M., Lehours, P., Mégraud, F., Leow, A. H. R., Vadivelu, J., & Goh, K. L. (2016). Molecular and proteomic analysis of levofloxacin and metronidazole resistant Helicobacter pylori. Frontiers in Microbiology, 7, 2015.

Hu, Y., Zhang, M., Lu, B., & Dai, J. (2016). Helicobacter pylori and antibiotic resistance, a continuing and intractable problem. Helicobacter, 21(5), 349–363.

Ibrahim, M. E. (2024). Epidemiology, pathogenicity, risk factors, and management of Helicobacter pylori infection in Saudi Arabia. Biomolecules and Biomedicine, 24(3), 440–453.

Karpiński, T. M., Andrzejewska, E., Eder, P., Linke, K., & Szkaradkiewicz, A. (2015). Evaluation of antimicrobial resistance of Helicobacter pylori in the last 15 years in West Poland. Acta Microbiologica et Immunologica Hungarica, 62(3), 287–293.

Kim, S. Y., Joo, Y. M., Lee, H. S., Chung, I.-S., Yoo, Y.-J., Merrell, D. S., & Cha, J.-H. (2009). Genetic analysis of Helicobacter pylori clinical isolates suggests resistance to metronidazole can occur without the loss of functional rdxA. The Journal of Antibiotics, 62(1), 43–50.

Kotilea, K., Bontems, P., & Touati, E. (2019). Epidemiology, diagnosis and risk factors of Helicobacter pylori infection. In: Kamiya, S. & Backert, S. (Eds.). Helicobacter pylori in human diseases. Springer, Cham. Pp. 17–33.

Kouitcheu Mabeku, L. B., Noundjeu Ngamga, M. L., & Leundji, H. (2018). Potential risk factors and prevalence of Helicobacter pylori infection among adult patients with dyspepsia symptoms in Cameroon. BMC Infectious Diseases, 18(1), 278.

Landstedt, K., Sharma, A., Johansson, F., Stålsby Lundborg, C., & Sharma, M. (2017). Antibiotic prescriptions for inpatients having non-bacterial diagnosis at medicine departments of two private sector hospitals in Madhya Pradesh, India: A cross-sectional study. BMJ Open, 7(4), e012974.

Liang, C.-M., Tai, W.-C., Hsu, P.-I., Wu, D.-C., Kuo, C.-H., Tsay, F.-W., Lee, C.-L., Chen, K.-Y., & Chuah, S.-K. (2020). Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: A multicentre report from Taiwan. Therapeutic Advances in Gastroenterology, 13, 1756284820976990.

Marshall, B., & Warren, J. R. (1984). Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. The Lancet, 323(8390), 1311–1315.

Martin, M., Grunendahl, M., & Martin, P. (2001). Age differences in stress, social resources, and well-being in middle and older age. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 56(4), 214–222.

Mégraud, F., Alix, C., Charron, P., Bénéjat, L., Ducournau, A., Bessède, E., & Lehours, P. (2021). Survey of the antimicrobial resistance of Helicobacter pylori in France in 2018 and evolution during the previous 5 years. Helicobacter, 26(1), e12767.

Miendje Deyi, V. Y., Bontems, P., Vanderpas, J., De Koster, E., Ntounda, R., Van Den Borre, C., Cadranel, S., & Burette, A. (2011). Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium. Journal of Clinical Microbiology, 49(6), 2200–2209.

Miendje Deyi, V. Y., Lare, M. S., Burette, A., Ntounda, R., Elkilic, O., Cadranel, S., Bontems, P., & Hallin, M. (2019). Update of primary Helicobacter pylori resistance to antimicrobials in Brussels, Belgium. Diagnostic Microbiology and Infectious Disease, 95(4), 114875.

Miftahussurur, M., Syam, A. F., Nusi, I. A., Makmun, D., Waskito, L. A., Zein, L. H., Akil, F., Uwan, W. B., Simanjuntak, D., Wibawa, I. D., Waleleng, J. B., Saudale, A. M., Yusuf, F., Mustika, S., Adi, P., Maimunah, U., Maulahela, H., Rezkitha, Y. A., Subsomwong, P., Nasronudin, … Yamaoka, Y. (2016). Surveillance of Helicobacter pylori antibiotic susceptibility in Indonesia: Different resistance types among regions and with novel genetic mutations. PloS One, 11(12), e0166199.

Mollin, A., Katta, M., Sobel, J. D., & Akins, R. A. (2022). Association of key species of vaginal bacteria of recurrent bacterial vaginosis patients before and after oral metronidazole therapy with short- and long-term clinical outcomes. PLoS One, 17(7), e0272012.

Parra-Sepúlveda, C., Merino, J. S., Sáez-Carrillo, K., González, C., & García-Cancino, A. (2019). Antibiotic resistance surveillance of Helicobacter pylori at the Biobío Region (Chile) in a decade. Arquivos de Gastroenterologia, 56(4), 361–366.

Regnath, T., Raecke, O., Enninger, A., & Ignatius, R. (2017). Increasing metronidazole and rifampicin resistance of Helicobacter pylori isolates obtained from children and adolescents between 2002 and 2015 in southwest Germany. Helicobacter, 22(1), e12327.

Saber, F. O., & Ali, M. K. (2022). Isolation and identification of H. pylori among Iraq patients with chronic gastric inflammation. Journal of the Faculty of Medicine Baghdad, 64(2), 102–108.

Saracino, I. M., Fiorini, G., Zullo, A., Pavoni, M., Saccomanno, L., & Vaira, D. (2020). Trends in primary antibiotic resistance in H. pylori strains isolated in Italy between 2009 and 2019. Antibiotics, 9(1), 26.

Savoldi, A., Carrara, E., Graham, D. Y., Conti, M., & Tacconelli, E. (2018). Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and meta-analysis in World Health Organization regions. Gastroenterology, 155(5), 1372–1382.

Schubert, J. P., Warner, M. S., Rayner, C. K., Roberts-Thomson, I. C., Mangoni, A. A., Costello, S., & Bryant, R. V. (2022). Increasing Helicobacter pylori clarithromycin resistance in Australia over 20 years. Internal Medicine Journal, 52(9), 1554–1560.

Semino-Mora, C., Doi, S. Q., Marty, A., Simko, V., Carlstedt, I., & Dubois, A. (2003). Intracellular and interstitial expression of Helicobacter pylori virulence genes in gastric precancerous intestinal metaplasia and adenocarcinoma. The Journal of Infectious Diseases, 187(8), 1165–1177.

Seriki, A. T., Smith, S. I., Adeleye, A. I., & Fowora, M. A. (2018). Molecular analysis of low-level tetracycline resistance in clinical isolates of Helicobacter pylori among dyspeptic patients in South West Nigeria. Journal of Global Antimicrobial Resistance, 13, 143–145.

Şeyda, T., Derya, Ç., Füsun, A., & Meliha, K. (2007). The relationship of Helicobacter pylori positivity with age, sex, and ABO/Rhesus blood groups in patients with gastrointestinal complaints in Turkey. Helicobacter, 12(3), 244–250.

Shokrzadeh, L., Jafari, F., Dabiri, H., Baghaei, K., Zojaji, H., Alizadeh, A., Aslani, M., & Zali, M. (2011). Antibiotic susceptibility profile of Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran. Saudi Journal of Gastroenterology, 17(4), 261–264.

Sholeh, M., Maleki, F., Krutova, M., Bavari, S., Golmoradi, R., Sadeghifard, N., Amiriani, T., & Kouhsari, E. (2020). The increasing antimicrobial resistance of Helicobacter pylori in Iran: A systematic review and meta-analysis. Helicobacter, 25(5), e12730.

Tran, T. T., Nguyen, A. T., Quach, D. T., Pham, D. T.-H., Cao, N. M., Nguyen, U. T.-H., Dang, A. N.-T., Tran, M. A., Quach, L. H., Tran, K. T., Le, N. Q., Ung, V. V., Vo, M. N.-Q., Nguyen, D. T., Ngo, K. D., Tran, T. L., & Nguyen, V. T. (2022). Emergence of amoxicillin resistance and identification of novel mutations of the pbp1A gene in Helicobacter pylori in Vietnam. BMC Microbiology, 22(1), 41.

Tshibangu-Kabamba, E., & Yamaoka, Y. (2021). Helicobacter pylori infection and antibiotic resistance – From biology to clinical implications. Nature Reviews Gastroenterology and Hepatology, 18(9), 613–629.

Wang, D., Guo, Q., Yuan, Y., & Gong, Y. (2019). The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer. BMC Microbiology, 19(1), 152.